AMGN vs PFE
Amgen and Pfizer, both Healthcare
Amgen is the larger company at $237B against $171B. On trailing earnings AMGN is the cheaper of the two at a P/E of 27.3 against 39.5, a gap that is only a bargain if the two are growing at similar rates. Over the past year AMGN returned +52% against +30% for PFE. The RyuScore puts AMGN ahead, 62 against 59 out of 100.
| Figure | AMGN | PFE |
|---|---|---|
| Last close | $439 | $30.02 |
| Market cap | $237B | $171B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 27.3 | 39.5 |
| Dividend yield | 2.2% | 5.8% |
| 1-year return | +52% | +30% |
| 5-year return | +147% | -8.6% |
| RyuScoresector-relative, 1–10 | 62/100 | 59/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Amgen
Revenue of $10B in Q2 2026, net income $2.4B. Its largest reported line is Other Products, 17% of the disclosed total.
Pfizer
Revenue of $15B in Q2 2026, net income null. Its largest reported line is Eliquis, 16% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.